RYMED TABLET

FDA nonproprietary name: dexchlorpheniramine maleate and phenylephrine hydrochloride

For 30 tablets

Pharmacies pay

$6.72 filed

30 × $0.22396 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01 · as of 2026-10-14 · retrieved 2026-10-17

Medicare

We don’t know yet

No Medicare reference price. Part D: OpenBill did not match this NDC to a usable Medicare Part D spending row. Either Part D has none for it, or the rows that share its name could not safely be tied to it (for example, they mix units, routes or release forms, or the drug is sold over the counter, which Part D does not cover). Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.

The spread

We don’t know yet

There is no Medicare figure to compare with, so there is no spread.

Cost-plus estimate

$12.73 estimated

$6.72 + $1.01 (15%) + $5.00 fee per fill = $12.73

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-01-01 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

RYMED TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as dexchlorpheniramine maleate and phenylephrine hydrochloride, under the trade name “RYMED”.

FDA gives its dosage form as tablet, coated and its route as oral.

The labeler, the company named on the label, is EDWARDS PHARMACEUTICALS, INC.

FDA’s Established Pharmacologic Class for it is alpha-1 Adrenergic Agonist.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00485-0080-01.

NADAC classes it as a brand-name drug (rate-setting class B), and marks it as sold over the counter.

What pharmacies pay

Pharmacies pay $6.72 for 30 tablets (30 × $0.22396 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-01-01. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 4, carried forward from the previous file; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.

This NDC’s NADAC was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2026-01-01. The file is new; the price is not.

What NADAC measures · Why 30 tablets · NADAC explanation codes · Carried-forward prices

The NDC

00485-0080-01 · EDWARDS PHARMACEUTICALS, INC. · $0.22396 per EA · eff. 2026-01-01 filed carried forward

Compared with its class

Its NADAC price is $0.22396 per EA filed.

Of the 47 other products in FDA’s alpha-1 Adrenergic Agonist class priced per EA, 8 have a higher middle NADAC price and 39 a lower one. The one in the middle is QC COLD HEAD CONGST SEVR CPLT, at $0.11111 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

We don’t know yet; the card above says why.

Which Medicare figure OpenBill compares · How Part D is matched · How Part B is matched

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
It is sold over the counter, so shelf prices vary from store to store: what does it cost per unit here?
These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.

Its pharmacologic class

alpha-1 Adrenergic Agonist 86 products